Alyeska Investment Group
AYTU icon

Alyeska Investment Group’s AYTU BioPharma AYTU Stock Holding History

Alyeska Investment Group’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-81,628
Closed -$238K – 533
2024
Q2 		$238K Buy
+81,628
New +$246K ﹤0.01% 526
2024
Q1 		– Sell
-81,628
Closed -$232K – 469
2023
Q4 		$232K Buy
+81,628
New +$225K ﹤0.01% 467

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alyeska Investment Group's AYTU Position: Q2 2023 in Review

Alyeska Investment Group sold out of AYTU BioPharma (AYTU) in Q2 2023, closing a stake of 75,000 shares — an estimated $168K sold.

Alyeska Investment Group first reported a position in AYTU in Q3 2022 and held it in 3 quarters. The position peaked at $284K in Q4 2022. 21 funds tracked by Wall St. Rank hold AYTU as of Q2 2023.

  • Alyeska Investment Group reported no remaining AYTU BioPharma position as of Q2 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 AYTU BioPharma shares in Q2 2023, an estimated $168K.
  • Alyeska Investment Group first reported a position in AYTU BioPharma in Q3 2022 and held it in 3 quarters.
  • Alyeska Investment Group's AYTU BioPharma position peaked at $284K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.